Hepatic steatosis detected on low‐dose computed tomography in high‐risk participants of a lung cancer screening programme: a retrospective observational study

Moderate to severe hepatic steatosis was detected on low-dose computed tomography (LDCT) in 15% of participants undergoing lung cancer screening in a retrospective observational study. Almost half of participants with hepatic steatosis (21/45) were at intermediate risk of liver fibrosis, with four participants (8.9%) at high risk based on Fibrosis-4 scores. Based on current guidelines, these participants would be recommended to undergo further evaluation for liver disease. The clinical impact of moderate to severe hepatic steatosis incidentally detected on lung cancer screening LDCT requires further consideration and evaluation.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2025-12-13
DOI
https://doi.org/10.1111/imj.70263
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hepatic steatosis detected on low‐dose computed tomography in high‐risk participants of a lung cancer screening programme: a retrospective observational study

Stephen Lam, Emily C.A. Stone, Michelle Chua, Annette M. McWilliams et al.
Internal Medicine Journal
Liver Disease Diagnosis and Treatment
article

Hepatic steatosis detected on low‐dose computed tomography in high‐risk participants of a lung cancer screening programme: a retrospective observational study

Stephen Lam, Emily C.A. Stone, Michelle Chua, Annette M. McWilliams, Henry Marshall, Diane Pascoe, Renée Manser, Siddharth Sood, Fraser Brims, Asha Bonney, Daniel Steinfort, Kwun M. Fong, Mark McCusker, Paul Fogarty
article en

Abstract

Moderate to severe hepatic steatosis was detected on low-dose computed tomography (LDCT) in 15% of participants undergoing lung cancer screening in a retrospective observational study. Almost half of participants with hepatic steatosis (21/45) were at intermediate risk of liver fibrosis, with four participants (8.9%) at high risk based on Fibrosis-4 scores. Based on current guidelines, these participants would be recommended to undergo further evaluation for liver disease. The clinical impact of moderate to severe hepatic steatosis incidentally detected on lung cancer screening LDCT requires further consideration and evaluation.

Internal Medicine JournalVol. 56(1)
The Royal Melbourne Hospital (AU), University of British Columbia (CA), The University of Melbourne (AU), Northern Health (AU), Curtin University (AU), Epworth Hospital (AU), Fiona Stanley Hospital (AU), Sir Charles Gairdner Hospital (AU), St Vincent's Clinic (AU), Prince Charles Hospital (AU), Institute for Respiratory Health (AU)
Openalex Percentile: Top 48%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.